Physician Scientist, passion for science, a life devoted to patients care.
Buenos Aires City Region, Argentina
Joined May 2017
- Tweets486
- Following107
- Followers248
- Likes1.4K
Silvia Sookoian retweeted
New online! Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management dlvr.it/TRb1CM
Agree! Emad has been an awesome EIC! Thank you Emad for your leadership and great work. Looking forward to the incoming editors. The team looks amazing.
Words cannot really express how sad I am that @emadelomar is retiring - an absolute legend and someone I hugely admire not just as an EIC but as a person. Emad is simply the best! Looking forward to working with Bill, Matias and Thomas (BMT) - I am sure they will be amazing
Silvia Sookoian retweeted
Semaglutide for #MASH - metabolic steatohepatitis @AghemoAlessio @SSookoian @LiverInt @policlinicoMI pubmed.ncbi.nlm.nih.gov/4114…
Silvia Sookoian retweeted
Exciting news! "Clinical and Molecular Hepatology" has achieved a 2024 Impact Factor of 16.9, ranking 6th out of 143 in Gastrenterology & Hepatology.
Thank you all for your continued support and contributions. Let’s continue this journey together by advancing knowledge and driving impactful research!
#ResearchCommunity #ImpactFactor #CMH #KASL
Silvia Sookoian retweeted
Avances en la enfermedad conocida como hígado graso.
Científicos del @CONICETDialoga y de UMAI identifican una proteína que asocia la esteatosis hepática, conocida como hígado graso, con complicaciones en órganos vitales. @SSookoian @ValeriaRoman @EduPeriodista @norabar
Silvia Sookoian retweeted
Hoy, en la Academia Nacional de Medicina le entregamos el Doctorado Honoris Causa a Luis Acero, prestigioso médico español especialista en Cirugía Buco Maxilofacial. Participaron de esta ceremonia el Dr. Eduardo Rey, Adrián Giacchino, Lino Barañao, Tomás Ameigeiras y @SSookoian
Silvia Sookoian retweeted
With @ArunJSanyalVCU, @SSookoian, @cjpirola. A call to recognize MASLD/MASH as a NCD. #livertwitter New in @NatRevGastroHep
New online! MASLD as a non-communicable disease bit.ly/3WPHaz0
Alimentary Pharmacology & Therapeutics | Pharmacology Journal | Wiley Online Library onlinelibrary.wiley.com/doi/…
Thank you for sharing this!
#CGH4ALL📣💥
A complete and thorough review of genetics🧬& MASLD @AGA_CGH🔥!
🔗doi.org/10.1016/j.cgh.2024.0…
#MASLD #livertwitter #GITwitter
Reported by @ifrahfatima
@SSookoian
@lucavalenti75
@scottisaacsmd
@ArunJSanyalVCU
@BrettEFortuneMD
@Dr_Vijay_Shah
@DougSimonetto
@SanjayaSatapath
Silvia Sookoian retweeted
Remember to screen first degree relatives for case finding of advanced #masld @stefano_romeo76 @SSookoian @NASH_and_coffee
#CGH4ALL @AGA_CGH📣
In relatives of pts w/ adv. Fibrosis or HCC 2/2 MASLD:
💡56.8% MASLD Prevalence
💡14.4% adv fibrosis
DM🍭BMI🍐may be some common risk factors
Could not identify polygenic risk factors
🔗doi.org/10.1016/j.cgh.2023.1…
#LiverTwitter #MASLD
Report @talal_khurshid
Awesome 🤩 @stefano_romeo76 . Absolutely agree. @lucavalenti75
Our best work so far! nature.com/articles/s41591-0…
👏🏻Congrats Federica, @stefano_romeo76 @lucavalenti75 and teamwork. Excellent work!!!
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
Nice review! Congratulations @lucavalenti75 and team.
ONLINE NOW: Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease dlvr.it/T8SJrt
Thank you @NODGastro and Kerry, great EICs for this opportunity to share with you and some other talented people this awesome task.
This Post is from an account that no longer exists. Learn more
Silvia Sookoian retweeted
Never underestimate the gut microbiome's potential impact.
New @NatureMedicine
A younger metabolic age gut microbiome counters cardiovascular risk in older adults
nature.com/articles/s41591-0…
Silvia Sookoian retweeted
The first drug approved for MASH, along with the global toll of this disease, summarized (e.g. ~30% of world population w/ MAFLD)
cell.com/cell/fulltext/S0092…
Especialistas del CONICET analizan en <i>Cell</i> las perspectivas del primer fármaco para tratar la enfermedad del hígado graso en su estadio más avanzado conicet.gov.ar/especialistas…. Muchas gracias @CONICETDigital por compartir. Ciencia 🇦🇷 ! Agradecidos a @CellCellPress
Resmetirom for treatment of MASH sciencedirect.com/science/ar… Honored by the invitation to summarize with @cjpirola this achievement from the biological perspective and implications. Thank you @CellCellPress and of course the brilliant team of the Resmetirom trial!
Thank you patients and advocacy groups, and nurses and doctors who made this possible. @fattyliverday @FattyLiverA
